Baseline Characteristics | Entire cohort | AIDS-related mortality | Non-AIDS-related mortality | All-cause mortality |
---|---|---|---|---|
Overall | 1160 (100)* | 251 (21.6) | 140 (12.1) | 391 (33.7) |
Gender | ||||
 Men | 857 (73.9) | 215 (25.1) | 136 (15.9) | 351 (41.0) |
 Women | 303 (26.1) | 36 (11.9) | 4 (1.3) | 40 (13.2) |
Age | ||||
 Median (Q1, Q3) | 34 (29–40) | 36 (30–43) | 35 (30–41) | 35 (30–42) |
 < 30 | 309 (26.6) | 55 (17.8) | 34 (11.0) | 89 (28.8) |
 30–39 | 545 (47.0) | 108 (19.8) | 61 (11.2) | 169 (31.0) |
 > =40 | 306 (26.4) | 88 (28.8) | 45 (14.7) | 133 (43.5) |
Marital status | ||||
 Married | 526 (45.3) | 101 (19.2) | 48 (9.1) | 149 (28.3) |
 Single | 303 (26.2) | 81(26.7) | 50 (16.5) | 131 (43.2) |
 Widowed/divorced | 331 (28.5) | 69 (20.8) | 42 (12.7) | 111 (3.4) |
Education | ||||
 Less than secondary | 403 (34.7) | 93 (23.0) | 50 (12.4) | 143 (35.5) |
 Secondary or more | 757 (65.3) | 158 (20.8) | 90 (11.8) | 237 (31.3) |
Employment | ||||
 Employed | 549 (47.3) | 112 (20.4) | 77 (14.0) | 189 (34.4) |
 Unemployed | 611 (52.7) | 139 (22.7) | 63 (10.3) | 202 (33.1) |
Incarceration history | ||||
 No | 392 (33.8) | 48 (12.2) | 10 (2.6) | 58 (14.8) |
 Yes | 768 (66.2) | 203 (26.4) | 130 (16.9) | 333 (43.4) |
Mode of HIV transmission | ||||
 Sexual | 344 (29.7) | 46 (13.4) | 9 (2.6) | 55 (16.0) |
 Injection drug use | 733 (63.2) | 185(25.2) | 123 (16.8) | 308 (42.0) |
 Othersa | 83 (7.1) | 20 (24.1) | 8 (9.6) | 28(33.7) |
 CD4 count Median (Q1, Q3) | 215 (102,352) | 238 (127,254) | 133 (63,260) | 163 (78,300) |
Year HIV was diagnosed | ||||
 Before 2011 | 712 (61.4) | 46 (6.4) | 35 (4.9) | 81 (11.3) |
 2011–2014 | 306 (26.4) | 145 (47.3) | 69 (22.5) | 214 (69.8) |
 2015–2017 | 142 (12.2) | 60 (42.2) | 36 (25.3) | 96(67.5) |
Covariates measured at follow-up | ||||
 Drug use status | ||||
  No drug use | 307 (26.5) | 36 (11.7) | 5 (1.6) | 41 (16.0) |
  On methadone therapy | 568 (49.0) | 101 (17.8) | 65 (11.4) | 166 (42.0) |
  Drug users | 258 (24.5) | 114 (44.2) | 70 (27.1) | 184 (33.7) |
Linkage to HIV care | ||||
 No | 219 (18.9) | 124 (56.6) | 72 (32.9) | 196 (89.5) |
 Yes | 941(81.1) | 127 (13.5) | 68 (7.2) | 195 (20.7) |
Responded HAART 6 month after initiationb | ||||
 No | 392 (33.8) | 239 (61) | 97 (24.7) | 232 (59.2) |
 Yes | 768 (66.2) | 12 (1.6) | 43 (5.6) | 159 (20.7) |
Late HIV diagnosis | ||||
 No | 629 (54.2) | 136 (21.6) | 96 (15.3) | 232 (36.9) |
 Yes | 531 (45.8) | 115 (21.7) | 44 (8.3) | 159 (29.9) |
TB status | ||||
 Negative | 1048 (90.3) | 205 (19.6) | 123 (11.7) | 328 (31.3) |
 Positive | 112 (9.7) | 46 (41.0) | 17 (15.2) | 63 (56.3) |
PCP prophylaxis | ||||
 No | 480 (41.4) | 108 (22.5) | 77 (16.0) | 185 (38.5) |
 Yes | 680 (58.6) | 143 (21) | 63 (9.3) | 206 (30.3) |
HCV positive co-infection | ||||
 Negative | 500 (43.1) | 116 (23.2) | 33 (6.6) | 149 (29.8) |
 Positive | 660 (56.9) | 135 (20.5) | 107 (16.2) | 242 (36.7) |
HBV positive co-infection | ||||
 Negative | 1078 (92.9) | 231 (21.4) | 127 (11.8) | 358 (33.2) |
 Positive | 82 (7.1) | 20 (24.4) | 13 (15.9) | 33 (40.2) |
Last clinical stage | ||||
 1,2 | 832 (71.7) | 24 (2.9) | 91 (10.9) | 115 (13.8) |
 3,4 | 328 (28.3) | 227 (69.2) | 49 (14.9) | 276 (84.1) |